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Classically, Toxoplasma infection is associated with high levels of specific IgM antibody and a rise in specific IgG levels 1 to 3
weeks later. Atypical IgG seroconversion, without IgM detection or with transient IgM levels, has been described during sero-
logic follow-up of seronegative pregnant women and raises difficulties in interpreting the results. To evaluate the frequency and
the characteristics of these atypical cases of seroconversion, an investigation was conducted within the French National Refer-
ence Center for Toxoplasmosis, fromwhich 26 cases collected from 12 laboratories belonging to the network were identified. The
aim of this work was to retrospectively analyze the results of serologic testing, the treatments administered, and the results of
prenatal and postnatal follow-up for these women. In each case, IgG antibodies were detected using both screening and confir-
matory tests. IgM antibodies were not detected in 15 cases, and the levels were equivocal or low-positive in 11 cases. The IgG
avidity results were low in 16 cases and high in one case. Most of the pregnant women (22/26) were treated with spiramycin from
the time that IgG antibodies appeared until delivery. Amniotic fluid was analyzed for Toxoplasma gondiiDNA by PCR in 11/26
cases, and the results were negative in all cases. Congenital toxoplasmosis was ruled out in 12/26 newborns. There was no abnor-
mality observed at birth for 10 newborns and no information available for 4 newborns. In conclusion, when the interpretation of
serological results is so difficult, it seems cautious to initiate treatment by spiramycin and to follow the pregnant women and
their newborns.
Primary toxoplasmic infection during pregnancy can inducetransplacental transmission of Toxoplasma gondii, resulting in a
congenital infection (1, 2, 3) with possible severe outcomes for the
fetus, including chorioretinitis, intracranial calcifications, hydro-
cephalus, and even stillbirth, especially if the congenital infection is
acquired early in the pregnancy (4, 5, 6). The majority of infants
infected later in pregnancy are asymptomatic at birth, with sequelae
potentially occurring later in life (7, 8, 9, 10). Since pregnant women
are generally asymptomatic during the course of Toxoplasma infec-
tion, the diagnosis is based on serological methods (11). Thus, sero-
negativewomencanbemonitoredduringpregnancy andprophylac-
tic recommendations provided (2). Consequently, serological tests
for IgM and IgG antibodies against T. gondii are commonly used as
initial screening approaches in the laboratory diagnosis of toxoplas-
mosis. IgM anti-T. gondii antibodies are known to be a marker of
acute infection and appear earlier and decline faster than IgG anti-
bodies. IgMis frequently thefirst antibody isotype tobedetectedafter
the primary infection. The diagnosis of recently acquired toxoplas-
mosis is usually based on the detection of specific IgM antibodies,
followed by the detection of specific IgG antibodies 1 to 3weeks later
with confirmatory tests as described by the French National Refer-
ence Center for Toxoplasmosis (12). Toxoplasma seroconversion is
thus defined by specific IgG antibodies appearing after IgM antibod-
ies (2).
However, the serological diagnosis of toxoplasmosis is very
complex and has been discussed extensively in the published lit-
erature (13, 14, 15). The interpretation of serological tests is com-
plicated by the long-term persistence of specific IgM and the de-
tection of either IgM alone or IgG alone in a previously
seronegative pregnant woman (2). Consequently, serological tests
other than those for IgG and IgM detection have been developed
to facilitate the diagnosis of seroconversion. The measurement of
IgG avidity was developed almost 20 years ago to exclude any
infection acquired in the preceding 3 or 4 months using most
commercial tests (16, 17, 18, 19, 20, 21, 22, 23, 24). Immunoblot
analysis (Toxo II IgG test; LDBio, Lyon, France) may promptly
confirm the seroconversion when IgG concentrations detected
with routine tests are negative or equivocal (25, 26, 27). In fact, the
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appearance of IgM alone might be difficult to interpret because it
can be due to nascent toxoplasmosis seroconversion or a nonspe-
cific IgM reaction (28).
Detection of anti-Toxoplasma IgG antibodies alone in previ-
ously seronegative pregnant women is so rarely observed that the
serological interpretation is difficult. With the exception of cases
of immunoglobulin injections and blood transfusions reported in
the literature (29), no data have been published showing the pres-
ence of anti-Toxoplasma IgG antibodies with negative or border-
line IgM titers in a pregnant woman known to be negative for
Toxoplasma antibodies shortly before that test. Laboratories of the
French National Reference Center for Toxoplasmosis have been
confronted with this situation in their routine work. To investi-
gate these complex situations, we surveyed these laboratories.
Twelve of them submitted 26 cases of atypical results obtained in
the serodiagnosis of toxoplasmosis over a 10-year period (2001-
2011). Thus, the aim of our work was to analyze the serological
results as they have been presented in real practice, the treatments
prescribed to the pregnant women, and the results of prenatal and
postnatal follow-up of these cases of atypical seroconversion with
negative or borderline IgM titers.
MATERIALS AND METHODS
Patients.We analyzed the results of serological testing in the 48 laborato-
ries of the French National Reference Center for Toxoplasmosis in order
to evaluate their difficulties in interpreting atypical seroconversions in
their daily practice of toxoplasmosis diagnosis. Ten towns (twelvemedical
centers) responded to our request, and we collected 26 cases of serocon-
version with negative or low-positive IgM titers among approximately
4,500 seroconversions detected between 2001 and 2011 (0.58%). The
number of exceptional serological patterns (IgG seroconversion in the
absence of an IgM response) was low at 26 of approximately 800,000
patients tested (1,200,000 serologies). The serological results of 120 serum
samples collected from the 26 patients were analyzed. These 26 cases had
been selected because the IgG tests were negative with at least one sample
and then positive with two to six samples, thus demonstrating a real sero-
conversion. The IgM tests were negative or borderline by screening or
confirmatory techniques.
Serological methods. A battery of serological tests, including screen-
ing and confirmatory tests, and referencemethods were performed by the
different laboratories for specific IgG, IgM, and IgA antibodies and IgG
avidity detection. IgG and IgM antibodies were detected by Vidas Toxo
IgG and IgM assays (bioMérieux, Marcy l’Etoile, France), Vidia Toxo IgG
and IgM assays (bioMérieux), AxSYM IgG and IgM assays (Abbott Diag-
nostic, Wiesbaden, Germany), Architect Toxo IgG and IgM assays (Ab-
bott Diagnostic), Cobas Toxo IgG and IgM assays (Roche Diagnostics,
Basel, Switzerland), Enzygnost Toxo IgG and IgM assays (Siemens
Healthcare Diagnostics, Deerfield, IL), Advia Centaur Toxo IgG and IgM
assays (Siemens), Platelia Toxo IgG and IgM assays (Bio-Rad, Marnes-la-
Coquette, France), and Liaison Toxo IgG and IgM assays (DiaSorin, Sa-
luggia, Italy). Confirmatory tests for IgG detection were the immunoflu-
orescence antibody test (IFAT) (produced in-house [29] or by
bioMérieux), the Toxo-Screen test (bioMérieux), the Toxo II IgG West-
ern blot test (LDBio, Lyon, France), the high-sensitivity direct agglutina-
tion (HSDA) test (house-made) (30, 31), and the Toxo indirect hemag-
glutination test (Fumouze Diagnostics, le Malesherbes, Levallois Perret,
France). The dye test, first described by Sabin and Feldman 60 years ago, is
still the referencemethod for specific antibody (IgG) detection. However,
this assay, based on live T. gondii, is now used in only a few laboratories
(two laboratories in our study). Confirmatory tests for IgMdetectionwere
the immunosorbent agglutination assay (ISAGA-M from bioMérieux or
ICT-M, an in-house immunocapture test for IgM [31]) and the immuno-
fluorescence antibody test (IFAT, produced by bioMérieux or in-house).
The IgA antibodies were detected by the ISAGA-A (bioMérieux), the
ICT-A (in-house) (31), or the Platelia Toxo IgA (Bio-Rad). In addition,
the level of IgG avidity was determined using the Vidas Toxo IgG avidity
assay (bioMérieux) in 4/10 laboratories, the Platelia Toxo IgG avidity
assay (Bio-Rad) in 2/10 laboratories, and the Architect Toxo IgG avid-
ity assay (Abbott Diagnostic) in 1/10 laboratories. All commercially avail-
able assays were performed according to the manufacturers’ recommen-
dations, and the results are expressed in IU/ml or as indices. The cutoff or
equivocal zone values of IgG, IgM, IgA, and IgG avidity are summarized in
Table 1.
Maternal treatment and prenatal diagnosis.Whenmaternal infection
acquiredduringpregnancywashighly suspected, themotherwas treatedwith
spiramycin at the standard dosage of 9 106 units per day until delivery (2).
In somecases, amniocentesiswasperformedafter16weeksof gestationandat
least 4 weeks after maternal infection (32). Prenatal diagnosis was based on
thedetectionofT.gondiiDNAbyPCR(33,34)and, inmost referencecenters,
on the detection of the parasite after mouse inoculation. Moreover, ultra-
sound surveillance was scheduled every month to carefully monitor fetal
development as recommended by the French National Reference Center
for Toxoplasmosis (see http://www.perinat-france.org/guide/cnr-centre
-national-de-reference-de-la-toxoplasmose-16-386.php).
Follow-up of newborns. At birth, each neonate underwent thor-
ough clinical and neurological check-ups (transfontanellar ultrasound
examination) and an examination of the ocular fundus. Parasitological
and immunological tests were used during the first year of life to
diagnose potential congenital toxoplasmosis (see reference 8 and http:
//www.perinat-france.org/guide/cnr-centre-national-de-reference-de
-la-toxoplasmose-16-386.php). Standard methods for the detection of
specific Toxoplasma antibodies (IgG, IgM, and IgA), such as the en-
zyme immunoassay (EIA) and immunosorbent agglutination assay
(ISAGA or ICT), were combined with Western blotting or an enzyme-
linked immunofiltration assay (ELIFA) (31) to distinguish maternal
antibodies, transmitted either passively (IgG) or by leakage (IgM), and
neonatal neosynthesized antibodies. The parasitological examination
of placental tissue was sometimes used to diagnose a congenital Toxo-
plasma infection at birth. However, serological follow-up of the in-
TABLE 1 Equivocal zone or cut-off values recommended by the
manufacturer of the Toxo IgG, Toxo IgM, Toxo IgG avidity, and Toxo
IgA assays
Technique
Equivocal zonea or cutoff value for indicated assay
Toxo IgG
(IU/ml) Toxo IgM (index)
Toxo IgG
avidity
(index)
Toxo IgA
(index)
Advia Centaur 10 0.9
Architect 1.6–2.9 0.50–0.59 0.50–0.59
AxSYM 2–2.9 0.5–0.6
Cobas 6
Dye test 2
Elecsys 1–2.9 0.8–0.9
Enzygnost 4 Determined for
each plate
HSDA 1–5
ICT 3 2
Immunofluorescence 6 or 8 1/40
ISAGA 6–8 6–8
Liaison 7.2–8.7 6.0–7.9
Platelia 6–8.9 0.8–0.9 0.40–0.49 6–8.9
Toxo screen DA 1–3
Vidas 4–7.9 0.55–0.64 0.20–0.29
Vidia 3–4.9 0.68–0.99
a In the equivocal zone, the lower value is the limit of negativity, and the higher value is
the limit of positivity.
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TABLE 2 Fifteen cases of atypical toxoplasmic seroconversion with negative IgM results by screening tests and the ISAGA testa
Case Date
Result for indicated assay
Toxo IgG Toxo IgM IgG avidity Toxo IgA
Advia
Centaur
Vidia Vidas AxSYM/
Liaison
Advia
Centaur
Vidia AxSYM ISAGA-M
1 06/20/09 2b 0.6
07/25/09 120c 0.6
08/20/09 270 204 212/159 0.6 0.2 4
09/16/09 64 0.17
Architect Vidas Platelia Elecsys Architect Vidas/IFAT Platelia/Elecsys ISAGA-M Vidas/Platelia/Architect ISAGA-A
2 12/07/09 0 0.125 0 /0
03/30/10 8.8 3 0.25 0.08/0 1 —/—/0.32
05/26/10 93.5 82 48 238.2 0.21 —/0 0.5/0 1 0.07/0.17/— 12
05/31/10 90.3 103 0.22 0/0 1 0.07/0.2/—
06/15/10 87 44 331.9 0.5/0 0.15/—/—
06/29/10 386.5 37 362.5 0.23 —/0 0.4/0 1 —/0.18/0.45 12
AxSYM Vidas HSDA AxSYM ICT-M Vidas ICT-A
3 09/12/05 0 0 0 0
10/08/05 0 0 0 0
11/11/05 4d 6 0.24 0 0
11/18/05 35 9 10 0.24 0 0
12/09/05 43 25 0.25 0 0.02 0
AxSYM Vidas HSDA AxSYM ICT-M Vidas ICT-A
4 11/05/07 0 0 0.081 0 0
12/19/07 0 0 0.081 0 0
01/26/08 7.8 1 0.081 0 0
02/20/08 19 25 10 0.081 0 0.08 0
02/28/08 0 0
Elecsys Platelia IFAT Elecsys Platelia ISAGA-M ISAGA-A
5 04/30/11 0.6 0
05/11/11 0.95 1.8 3 0 0.7
05/24/11 5.7 10 0.5 3 0
06/27/11 30.8 30 20 0 0.4 5 0
07/15/11 34 60 0.5
Vidas IFAT Vidas IFAT AxSYM ISAGA-M Vidas
6 12/01/01 0 0 0.07 0 0
12/28/01 10 8 0.1 0 0 0.55
01/07/02 85 8 0.14 0 0 0.54
01/26/02 135 8 0.16 0 0
02/28/02 83 8 0.16 0 0
04/15/02 39 8 0.12 0 0
Vidas IFAT Vidas IFAT ISAGA-M Vidas
7 05/17/03 0 0 0.47 0 0
06/20/03 26 8 0.49 0 0 0.06
07/10/03 44 8 0.43 0 0
AxSYM Vidia AxSYM Vidia ISAGA-M
8 06/22/06 2 0.28
09/27/06 2 0.39
10/16/06 5.1 0.42
12/01/06 35.7 0.36
01/18/07 168 0.34 0
AxSYM Toxo-Screen AxSYM ISAGA-M Vidas ISAGA-A
9 01/07/06 0 0.11 0 0
02/18/06 0 Negative 0.18 4 0
03/18/06 31 Positive 0.18 4 0
03/29/06 48 Positive 0.17 4 0.02 0
(Continued on following page)
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fants remained necessary to definitely diagnose the presence or ab-
sence of congenital toxoplasmosis in a few cases. When the results of
specific IgG (detection) tests became negative before the infants
reached the age of 1 year, congenital toxoplasmosis was definitively
ruled out.
RESULTS
Anti-Toxoplasma IgG results. Results of the anti-Toxoplasma
IgG tests concerning the 26 cases in this study are detailed in Ta-
bles 2, 3, and 4. In all cases for all techniques, the results of the first
serum samples were negative. Then, IgG antibodies appeared in
the second or third serum sample. In three cases (Table 2, case 15,
and Table 4, cases 21 and 26), anti-Toxoplasma IgG antibodies
were analyzed with only one technique, but two (case 15) or four
successive serum samples (cases 21 and 26) tested positive. In the
other 23 cases, analysis of anti-Toxoplasma IgG revealed positive
results using two to six different techniques on two to six succes-
sive serum samples. The confirmatory tests for IgG detection were
always positive (IFAT [7 cases], Toxo-Screen [3 cases], Toxo II
IgG Western blot [1 case], HSDA [7 cases], hemagglutination
[1 case], and dye test [2 cases]). The average IgG levels were quite
low regardless of which technique was used. In three cases
(11.5%), IgG antibodies were detected during the first trimester,
in 15 cases (57.7%) during the second trimester, and in eight cases
(30.8%) during the last trimester (Table 5). In all cases, the IgG
test results remained positive in the successive samples collected
over a time period ranging from 2 weeks to 6 months, depending
on the patient. Moreover, in one case (Table 4, case 18), not only
did varicella symptoms appear during the same time period as the
anti-Toxoplasma IgG, but IgG antibodies against the varicella-zos-
ter virus also appeared in the second serum sample, as did T.
gondii-specific IgG antibodies. The Vidas IgG results were very
low in this case; consequently, IgG avidity was not tested, as rec-
ommended by the manufacturer.
Anti-Toxoplasma IgM results. Between two and six tests for
IgM antibodies against T. gondii were performed on each serum
sample. An immunocapture test (ISAGA-M or ICT-M) was the
confirmatory test in all 26 cases. The patients were classified into
three categories according to the IgM results (Tables 2, 3, and 4).
TABLE 2 (Continued)
Case Date
Result for indicated assay
Toxo IgG Toxo IgM IgG avidity Toxo IgA
AxSYM Toxo-Screen AxSYM ISAGA-M Vidas ISAGA-A
10 03/27/07 0 Negative 0.10 0 0
04/05/07 1 Negative 0.11 0 0
04/25/07 34 Positive 0.12 1 0.07 0
05/03/07 47 Positive 0.113 1 0
05/18/07 75 0.116 0 0
AxSYM HSDA AxSYM ISAGA-M Vidas ISAGA-A
11 12/08/10 0 Negative 0.09 0 0
01/22/11 4 Positive 0.17 3 0
02/09/11 7 Positive 0.21 3 0
03/07/11 14 0.178 3 0.046 0
Vidas HSDA Vidas ICT-M Vidas ICT-A
12 08/14/08 0 0 0 0
09/11/08 2 10 0.55 0 0
10/09/08 65 100 0 0.02 0
10/22/08 200 0 0
Vidas HDSA Vidas ICT-M Vidas ICT-A
13 03/11/11 0 0 0 0 0
07/08/11 4 50 0.41 0 0
08/24/11 64 100 0.40 0 0.05 0
Platelia IFAT Platelia ISAGA-M Platelia ISAGA-A
14 01/18/10 0 0 0.2 0
03/08/10 1.6 2 0.5
04/08/10 11 6 0.3 3 0
04/20/10 29 10 0.2 5 0.12 7
Enzygnost Enzygnost ISAGA-M ISAGA-A
15 09/29/03 2.7 0.145 0 12
10/25/03 12 0.136 3 12
11/07/03 26 0.124 3 12
a Detailed results of IgG, IgM, IgA, and avidity index on 15 atypical seroconversion panels.
b Nonreactive results are not highlighted.
c Reactive results are in bold type and highlighted in gray.
d Equivocal zone results are in bold type.
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For 15 patients in the first category, the IgM results were negative
with the screening tests and the ISAGA-M or the ICT-M assay
(Table 2, cases 1 to 15). In the second category, including two
cases, the IgM results were slightly positive with two techniques
(Platelia and Liaison) and negative by three other techniques
(ISAGA-M, immunofluorescence, and Cobas) (Table 3, cases 16
and 17). In case 16, the Liaison IgM and Platelia IgM tests were
positive after IgG antibodies had appeared. In case 17, the Platelia
IgM test was positive in the first serum sample, with equivocal IgG
titers using the Liaison test. The Platelia IgM test results were then
equivocal and negative in the successive serum samples. The
Liaison IgM test results were equivocal in the next five samples. In
the third category, including nine cases, although the results of
IgM screening tests were negative or equivocal by one technique,
the ISAGA-M or ICT-M results were equivocal or positive in one
to four successive serum samples (Table 4, cases 18 to 26). In two
of nine cases (Table 4, cases 21 and 26), the ISAGA-M tests gave
positive or equivocal results for the first serum sample, and in the
remaining cases, IgM and IgG antibodies were observed simulta-
neously in the second serum samples. In 8/11 cases, decreasing
IgM values were observed.
Anti-Toxoplasma IgA results. The IgA assay (ISAGA-A,
ICT-A, or Platelia) was performed on 54 serum samples collected
from 16 patients. The results were negative for 10 patients, equiv-
ocal for one patient, and positive for five patients. The patient with
equivocal IgA results (case 14) had negative IgM results. Of the
five patients who tested positive for IgA, two (cases 2 and 15)
tested negative for IgM, two (cases 20 and 21) had positive IgM
results by only the ISAGA-M test, and one (case 24) had equivocal
IgM titers in the ISAGA-M test.
IgG avidity results.The IgG avidity assay was performed on 26
samples collected from 17 patients. Two serum samples from one
patient (case 6) revealed high avidity, while 24 samples from 16
patients exhibited low avidity. High avidity excluded a Toxo-
plasma infection acquired less than 4 months earlier.
Maternal treatment and prenatal diagnosis. Of the 26 pa-
tients, 22 (84.6%)were treatedwith spiramycin from the time that
the IgG appeared until delivery, and one received no treatment
(Table 5). We had no information about the treatment for three
patients. PCR analysis of the amniotic fluid was performed on
samples from 11 patients, and the results were always negative.
Amniotic fluid was not collected in 13 cases, and no information
was available in two cases.
Follow-up of newborns. The postnatal serological follow-up
period was long enough to definitively exclude congenital toxo-
plasmosis in 12 cases (Table 5). In 10 cases, biological, clinical,
radiological, and ophthalmological examinations of the newborns
at birth did not reveal any abnormalities, but no information was
available concerning their follow-up. In four cases, we had no
information about the newborns.
DISCUSSION
Serological diagnosis is the main approach for defining the risk of
primary Toxoplasma infection in a pregnant woman. The mea-
surement of IgG, IgM, IgA, and IgG avidity by different methods
usually allows doctors to establish the immunologic status of a
patient and to diagnose seroconversion (2). The difficulties en-
countered in the serodiagnosis of toxoplasmosis in pregnant
women have been underlined for a long time (15, 29, 35, 36). The
absence of IgG antibodies before, or early in, pregnancy enables
the identification of women at risk for acquiring infection (12).
Thus, in the daily routine, serological results showing positive IgG
and negative or transient IgM in previously negative pregnant
women can create interpretation difficulties.
Different factors might explain such results: (i) the injection of
gamma globulins or a blood transfusion, which might have led to
the appearance of exogenous anti-Toxoplasma IgG (29); (ii) im-
mune disorders or other pathologies in the patient, which might
have led to the presence of unusual antibody subsets; (iii) toxo-
plasmosis serological reactivation or reinfection in chronically in-
fected patients with previously very low IgG residual titers below
the detection threshold; and (iv) toxoplasmosis that was recently
acquired but with a very unusual serological profile. The first two
factors should be investigated before the others, and if appropri-
ate, the pregnant women should be considered seronegative and
TABLE 3 Two cases of atypical seroconversion with weakly positive IgM by two techniques (Platelia and Liaison) and negative by three other
techniques (ISAGA, immunofluorescence, and Elecsys)a
Case Date
Toxo IgG assay Toxo IgM index
Toxo IgG
avidity
PlateliaPlatelia Elecsys Liaison HSDA/dye test IFAT Platelia Elecsys Liaison ISAGA-M IFAT
16 04/02/09 2b 0.125 0 1/2 Negative 0.44 0.270 10 0 0
05/11/09 6 8/10 0.32 0
05/25/09 52c 16.47 70 64/100 Positive 0.72 0.370 18 0 0 0.13
05/29/09 57 84 Positive 0.81d 9 0 0 0.14
06/18/09 131 122 Positive 1.16 15 0 0 0.15
17 09/29/08 0 0.13 0 Negative 0 4 1 0
11/03/08 1 3 7.6 Positive 1.39 0 7 3 0
11/29/08 30 15 43.3 Positive 0.85 0 7 1 0 0.27
12/10/08 46 43 55.6 Positive 0.73 0 8 1 0 0.22
12/29/08 13 56.3 Positive 0.52 8 1 0 0.2
01/30/09 37.3 Positive 8 0
a Detailed results of IgG, IgM, IgA, and avidity index on 2 atypical seroconversion panels.
b Nonreactive results are not highlighted.
c Reactive results are in bold type and highlighted in gray.
d Equivocal zone results are in bold type.
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TABLE 4 Nine cases of atypical seroconversion with negative IgM by the screening techniques and positive or equivocal IgM by ISAGAa
Case Date
Result for indicated assay
Toxo IgG Toxo IgM
IgG
avidity Toxo IgA
Vidas IFAT AxSYM Vidas IFAT AxSYM ISAGA-M
18 04/27/10 0b 0 0.05 0 0
06/03/10 8 80c 0.13 0 0.3 9
06/21/10 6d 80 171 0.09 0 0.25 6
07/21/10 5 8 137 0.08 0 0.24 0
08/26/10 5 8 61 0.08 0 0.17 0
09/22/10 3 8 42 0.06 0 0.15 0
10/19/10 2 8 0.08 0 0
AxSYM Vidia Dye test/HSDA AxSYM Vidia ISAGA-M
19 01/26/08 0.4 2/1 0.06 0
03/01/08 3 5/1 0.56 9
03/22/08 21 80/8 0.53 9
08/28/08 28 0.45
Architect Vidia Western blot Hemagglutination Architect Vidia ISAGA-M ISAGA-A
20 07/30/11 0.1 0 Negative Negative 0.04 0.08 0
09/06/11 27 3.0 Positive Positive 0.20 0.76 9 6
09/30/11 114.2 Positive 0.22 5 9
Enzygnost Enzygnost Vidas ISAGA-M ISAGA-A
21 03/03/06 2.1 0.043 0.32 12 12
04/05/06 11 0.091 0.32 12 12
05/15/06 64 0.076 12 12
06/17/06 84 0.028 9 12
08/04/06 37 0.036 3 12
Advia Centaur Platelia Advia Centaur Platelia Vidas/IFAT ISAGA-M Platelia
22 01/25/10 0.5 0.72
02/22/10 4 0.85
03/18/10 46 0.87 0.51/10 12 0.01
04/08/10 48 0.95 6
06/02/10 33 0.919
Vidas IFAT Vidas IFAT ISAGA-M Vidas
23 03/22/01 0 0 0.12 0 0
05/02/01 73 160 0.37 0 7 0.03
05/28/01 195 320 0.32 0 6
09/03/01 157 320 0.18 0 3
Liaison Vidia Liaison Vidia ISAGA-M Platelia-A
24 08/02/07 2 8 ND
09/05/07 20 6 6 41
09/26/07 40 6 6 59
12/20/07 42 0.17 3
AxSYM Toxo-Screen AxSYM ISAGA-M Vidas ISAGA-A
25 09/24/04 0 Negative 0.125 0
10/28/04 0 Negative 0.145 0 0
01/04/05 8 Positive 0.224 6 0
01/10/05 14 Positive 0.285 6 0.05 0
02/11/05 60 0.314 7 0
03/04/05 68 0.323 7 0
Cobas Vidas ISAGA-M Vidas ISAGA-A
26 03/23/06 0 0.6 7
04/28/06 148 0 6 0.06
05/08/06 175 0 6
05/30/06 264 0 6
10/27/06 42 0 0 0
a Detailed results of IgG, IgM, IgA, and avidity index on 9 atypical seroconversion panels.
b Nonreactive results are not highlighted.
c Reactive results are bold type and highlighted in gray.
d Equivocal zone results are in bold type.
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be given hygiene recommendations to avoid toxoplasmic infec-
tion.
The first factor (injection of gamma globulins) was ruled out
for the 26 cases described in our study. Concerning immune dis-
orders or other pathologies, only varicella symptoms were ob-
served in 1/26 cases (Table 2, case 18). To our knowledge, while
viral infections are known to generate positive anti-Toxoplasma
IgM, no data can be found in the literature about the influence of
viral infection on the detection of anti-Toxoplasma IgG. The third
factor is toxoplasmic serological reactivation or reinfection. In
chronic toxoplasmosis, IgG could exceptionally decrease to below
the cutoff level of the IgG assay, and in such cases, the reappear-
ance of IgG is not a real seroconversion but a serological reactiva-
tion. An additional exposure to T. gondii could trigger an imme-
diate IgG responsewithout an (orwith aweak) IgM response (37).
In the case of high IgG avidity results and the absence of
gamma globulin injection or transfusion, IgG detection is the par-
amount criterion of chronic toxoplasmosis (12). In one case of
our study (Table 2, case 6), the result of the avidity assay was high,
but it is necessary to stress that high avidity has been observed, if
rarely, in serum sampled 1 month after infection (21). However,
the determination of IgG avidity in an atypical serological profile
is necessary (12).
The fourth factor (recently acquired toxoplasmosis with an
atypical serological profile) is often considered by medical biolo-
gists and clinicians. In fact, in our study, 22/26 patients were
treated with spiramycin as a consequence of such serological re-
sults, and an amniocentesis was performed for 11/26 patients.
However, the results of the infants’ follow-ups did not reveal any
case of congenital toxoplasmosis. In fact, our results definitively
excluded toxoplasmosis in 12 cases and revealed no neonatal ab-
normality or any serological argument for congenital toxoplas-
mosis at birth in 10 cases.
The results of IgG confirmatory techniques were always the
same as those of the IgG screening techniques, i.e., negative on the
first serum sample and positive on the other successive serum
samples. Moreover, the avidity findings were low in 16/17 cases.
Typically, in seroconversion, the appearance of IgG is linked to
high IgM and rising IgM levels (15). In our study, IgM antibodies
were not detected in 15 cases, although we cannot totally exclude
that they could have been transient and present during only a very
short time period so that they were not observed in the samples at
the time theywere collected. If the interval between two samplings
had been shorter, IgM might have been observed. In the 11 other
cases, IgM antibodies were detected at low levels by the Liaison
and Platelia tests (2 cases) or with a positive index by only the
ISAGA test (9 cases). The detection of IgM usually indicated tox-
oplasmosis. However, considering that these IgM antibodies were
TABLE 5 Gestational age at time of IgG conversion, maternal treatment, prenatal diagnosis, and infant follow-up of the 26 women with atypical
seroconversion
Patient
no.
Gestational age at IgG
conversion (wk of
amenorrhea)
Maternal treatment
by spiramycin
Prenatal
diagnosisa Infant follow-upb
1 29 NDc No No abnormality at birth
2 5 Yes ND ND
3 33 No No No congenital toxoplasmosis
4 20 Yes No No congenital toxoplasmosis
5 40 ND No No abnormality at birth
6 25 Yes Negative result No congenital toxoplasmosis
7 18 Yes Negative result No abnormality at birth
8 25 Yes No No abnormality at birth
9 18 Yes ND ND
10 10 Yes Negative result No congenital toxoplasmosis
11 28 Yes No ND
12 28 Yes Negative result No congenital toxoplasmosis
13 24 Yes Negative result No congenital toxoplasmosis
14 15 Yes Negative result ND
15 16 Yes Negative result No abnormality at birth
16 15 Yes No No abnormality at birth
17 16 Yes No No abnormality at birth
18 21 Yes No No abnormality at birth
19 14 Yes Negative result No congenital toxoplasmosis
20 36 Yes No No congenital toxoplasmosis
21 23 Yes Negative result No abnormality at birth
22 26 Yes Negative result No congenital toxoplasmosis
23 22 Yes Negative result No congenital toxoplasmosis
24 25 ND No No abnormality at birth
25 32 Yes No No congenital toxoplasmosis
26 12 Yes No No congenital toxoplasmosis
a Prenatal diagnosis was based on the PCR results and, in a few centers, results of inoculation of amniotic fluid into mice.
b Infant follow-up was based on clinical, radiological, ophthalmological, and biological examinations at birth. Serological results during the first year of life definitively excluded
congenital toxoplasmosis.
c ND, no data.
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detected at low levels for a very short time period and that they
tested positive with only one or two techniques (only the ISAGA
test or only the Platelia and Liaison tests) and quickly disappeared,
anti-Toxoplasma IgM antibodies were probably not specific. The
persistence of IgG in all successive serum samplesmight have sug-
gested a life-long immunity to toxoplasmosis, but the follow-up
time of these women was not long enough (from 2 weeks to 6
months, depending on the patient).
A pregnant woman who tests negative requires regular check-
ups for seroconversion (2). In fact, the frequency of check-ups
varies from one country to another, depending on the screening
programs adopted in each country. Seroconversion without IgM
can be observed in France thanks to monthly routine testing of
seronegative pregnant women. Such results in a previously sero-
negative pregnant woman should motivate further exploratory
tests, as defined by the French National Reference Center for Toxo-
plasmosis (12). Double-checking IgG results using other tech-
niques is necessary to confirm the first results, and the avidity test
is necessary. It is also important to collect all information about
the clinical history of a pregnant woman (immune disorders,
other pathology, transfusion, and previous results of toxoplasmo-
sis serology). The interpretation of seroconversion with either no
IgM or transient IgM levels may then be discussed.
It is noteworthy that the pathophysiology of toxoplasmosis is
far from being fully understood, and the pathogenesis mechanism
is complex because the parasite and host specificities are interre-
lated (38). In such complex serological cases as those that we an-
alyzed, we think that it is cautious to initiate treatment and to
follow up with pregnant women (4). Puncture and analysis of the
amniotic fluidmay also be discussed, depending on the gestational
age at which the IgG antibodies appeared.
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